|Bid||15.46 x 2900|
|Ask||16.00 x 800|
|Day's range||15.61 - 15.85|
|52-week range||1.04 - 15.85|
|PE ratio (TTM)||N/A|
|Earnings date||8 Aug 2017 - 14 Aug 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||14.67|
On a per-share basis, the Brisbane, California-based company said it had a loss of 30 cents. The molecular diagnostics company posted revenue of $14.1 million in the period, which topped Street forecasts. ...
On a per-share basis, the Brisbane, California-based company said it had a loss of $1.13. Losses, adjusted for non-recurring costs and stock option expense, came to 9 cents per share. The molecular diagnostics ...
The Zacks Analyst Blog Highlights: Aetna, CareDx, PRA Health Sciences and Diplomat Pharmacy
The Zacks Analyst Blog Highlights: BioLife Solutions, SeaSpine Holdings, Apollo Endosurgery and CareDx
In the wake of the turbulent political scenario and banking on favorable metrics, these four MedTech stocks stand out as the most suitable picks.
The Brisbane, California-based company said it had a loss of 63 cents per share. Losses, adjusted for non-recurring costs and costs related to mergers and acquisitions, came to 15 cents per share. The ...